ABOUT THE EVENT

Your Definitive Guide to Retinal Imaging Biomarkers & Endpoints

The 3rd Annual Retinal Imaging Biomarkers & Endpoints Summit is the premier industry forum dedicated to advancing retinal imaging technologies for biomarker discovery and clinical trial endpoints.

Uniting key experts from biotech, pharma, and academia, the event focuses on optimizing imaging modalities, improving regulatory pathways, and accelerating drug development in ophthalmology. Through interactive discussions, case studies, and the latest data, attendees will explore emerging imaging techniques, AI-driven analysis, and validation strategies.

Join us to collaborate on shaping the future of retinal imaging and advancing precision medicine for retinal diseases.

VIEW THE ALL NEW EVENT GUIDE FOR 2025

Join Our Expert Speakers for 3 Days of

3RD Retinal Imaging Biomarkers & Endpoints Summit

Learn from the industry’s leading retinal imaging specialists, data scientists, and AI experts, with speakers from Novartis, REGENXBIO, Novartis, Ocunexus, Bausch + Lomb, Galimedix, and more!

3RD Retinal Imaging Biomarkers & Endpoints Summit

The latest research on multimodal imaging and precision biomarkers to refine endpoints and enhance regulatory success

3RD Retinal Imaging Biomarkers & Endpoints Summit

Harness the power of AI and advanced analytics to refine and optimize patient selection, stratification, and clinical trial success for AMD, GA, DR, IRDs, and glaucoma

Who Will You Meet?

The 3rd Annual Retinal Imaging Biomarkers & Endpoints Summit connects clinical scientists, imaging scientists, medical directors, R&D, imaging technology and algorithm engineers focusing on spearheading their development.

3RD Retinal Imaging Biomarkers & Endpoints Summit

Previously Attending Companies Include

Hear What Your Peers Have to Say

Novartis, Retinal Imaging Biomarkers & Endpoints Summit

"This meeting offers both excellent networking opportunities as well as a chance to stay on top of developments in the field.”

Principal Scientist II, Novartis
 

Novartis, Retinal Imaging Biomarkers & Endpoints Summit
Boehringer Ingelheim, Retinal Imaging Biomarkers & Endpoints Summit

"Close exchange with colleagues from pharma and leading academics. I really appreciated that there was enough time for networking and discussion. Discussion after the talks had enough time and went deep in content.”

Global Therapeutic Area Head Retinal Health, Boehringer Ingelheim
 

Boehringer Ingelheim, Retinal Imaging Biomarkers & Endpoints Summit
Nanoscope Therapeutics, Retinal Imaging Biomarkers & Endpoints Summit

"Advanced imaging and identification of biomarkers for disease progression and evaluation of therapeutic efficacy are timely for the transformational therapies in horizon for retinal disease.”

Chief Scientific Officer, Nanoscope Therapeutics
 

Nanoscope Therapeutics, Retinal Imaging Biomarkers & Endpoints Summit
Forus Health, Retinal Imaging Biomarkers & Endpoints Summit

"Overall, the event was very well organized with sharp focus and emphasis on a few specific areas in retinal diseases clinical trials and treatment. Since it was a small and focused gathering, it was easy to network.”

Chief Technology Officer, Forus Health
 

Forus Health, Retinal Imaging Biomarkers & Endpoints Summit
Abeona Therapeutics, Retinal Imaging Biomarkers & Endpoints Summit

"Very high-quality discussion with industry-wide implications and the willingness for further collaboration.”

Director, Product Development, Abeona Therapeutics
 

Abeona Therapeutics, Retinal Imaging Biomarkers & Endpoints Summit
EVENT GUIDE
REGISTER
PARTNER